Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.28 EUR
−147.74 M EUR
0.00 EUR
39.60 M
About ABIVAX
Sector
CEO
Marc M. P. de Garidel
Headquarters
Paris
Website
Founded
2013
ISIN
FR0012333284
FIGI
BBG00GNG2LD0
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ABIVAX SA EO -,01 stocks are traded under the ticker 2X1.
We've gathered analysts' opinions on ABIVAX SA EO -,01 future price: according to them, 2X1 price has a max estimate of 48.66 EUR and a min estimate of 18.00 EUR. Watch 2X1 chart and read a more detailed ABIVAX SA EO -,01 stock forecast: see what analysts think of ABIVAX SA EO -,01 and suggest that you do with its stocks.
Yes, you can track ABIVAX SA EO -,01 financials in yearly and quarterly reports right on TradingView.
ABIVAX SA EO -,01 is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
2X1 earnings for the last half-year are −1.30 EUR per share, whereas the estimation was −1.37 EUR, resulting in a 5.34% surprise. The estimated earnings for the next half-year are −1.47 EUR per share. See more details about ABIVAX SA EO -,01 earnings.
ABIVAX SA EO -,01 revenue for the last half-year amounts to 6.64 M EUR, despite the estimated figure of 3.44 M EUR. In the next half-year revenue is expected to reach 2.37 M EUR.
2X1 net income for the last half-year is −81.64 M EUR, while the previous report showed −95.79 M EUR of net income which accounts for 14.77% change. Track more ABIVAX SA EO -,01 financial stats to get the full picture.
No, 2X1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 5, 2025, the company has 61.00 employees. See our rating of the largest employees — is ABIVAX SA EO -,01 on this list?
Like other stocks, 2X1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIVAX SA EO -,01 stock right from TradingView charts — choose your broker and connect to your account.